A role for cytochrome b5 in the in vivo disposition of anticancer and cytochrome P450 probe drugs in mice

Drug Metabolism and Disposition

Volumn 42, Issue 1, 2014, Pages 70-77

  Henderson, Colin J ^a   McLaughlin, Lesley A ^a   Finn, Robert D ^a,b   Ronseaux, Sebastien ^a,c   Kapelyukh, Yury ^a   Wolf, C Roland ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b NORTHUMBRIA UNIVERSITY   (United Kingdom)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; CHLORZOXAZONE; CYCLOPHOSPHAMIDE; CYTOCHROME B5; CYTOCHROME P450; GEFITINIB; METOPROLOL; MIDAZOLAM; PACLITAXEL; PHENACETIN; TAMOXIFEN; TOLBUTAMIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG METABOLISM; IN VIVO STUDY; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; CYTOCHROMES B5; HALF-LIFE; LIVER; MALE; MICE; MICE, INBRED C57BL; MICROSOMES, LIVER;

EID: 84890773913     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.055277     Document Type: Article

References (56)

1. Akhtar MK, Kelly SL, and Kaderbhai MA (2005) Cytochrome b(5) modulation of 17alpha hydroxylase and 17-20 lyase (CYP17) activities in steroidogenesis. J Endocrinol 187:267-274. (Pubitemid 41685186)
2. Arinç E, Pasha RP, Adali O, and Başaran N (1994) Stimulatory effects of lung cytochrome b5 on benzphetamine N-demethylation in a reconstituted system containing lung cytochrome P450LgM2. Int J Biochem 26:1033-1042.
3. Court MH, Von Moltke LL, Shader RI, and Greenblatt DJ (1997) Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species. Biopharm Drug Dispos 18: 213-226. (Pubitemid 27191802)
4. Crewe HK, Barter ZE, Yeo KR, and Rostami-Hodjegan A (2011) Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factors. Biopharm Drug Dispos 32:303-318.
5. Dehal SS and Kupfer D (1997) CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res 57:3402-3406. (Pubitemid 27355484)
6. Dekant W, Frischmann C, and Speerschneider P (1995) Sex, organ and species specific bio-activation of chloromethane by cytochrome P4502E1. Xenobiotica 25:1259-1265.
7. DeLozier TC, Tsao CC, Coulter SJ, Foley J, Bradbury JA, Zeldin DC, and Goldstein JA (2004) CYP2C44, a new murine CYP2C that metabolizes arachidonic acid to unique stereospecific products. J Pharmacol Exp Ther 310:845-854. (Pubitemid 39108903)
8. Dharia S, Slane A, Jian M, Conner M, Conley AJ, Brissie RM, and Parker CR, Jr (2005) Effects of aging on cytochrome b5 expression in the human adrenal gland. J Clin Endocrinol Metab 90:4357-4361. (Pubitemid 41058219)
9. Ding X and Kaminsky LS (2003) Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 43:149-173. (Pubitemid 37372638)
10. Emoto C and Iwasaki K (2007) Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: the effect of the expression of cytochrome b(5) with recombinant P450 enzymes. Xenobiotica 37:986-999. (Pubitemid 47482949)
11. Finn RD, McLaughlin LA, Ronseaux S, Rosewell I, Houston JB, Henderson CJ, and Wolf CR (2008) Defining the in Vivo Role for cytochrome b5 in cytochrome P450 function through the conditional hepatic deletion of microsomal cytochrome b5. J Biol Chem 283:31385-31393.
12. Finn RD, Henderson CJ, Scott CL, and Wolf CR (2009) Unsaturated fatty acid regulation of cytochrome P450 expression via a CAR-dependent pathway. Biochem J 417:43-54.
13. Finn RD, McLaughlin LA, Hughes C, Song C, Henderson CJ, and Roland Wolf C (2011) Cytochrome b5 null mouse: a new model for studying inherited skin disorders and the role of unsaturated fatty acids in normal homeostasis. Transgenic Res 20:491-502.
14. Forrester LM, Henderson CJ, Glancey MJ, Back DJ, Park BK, Ball SE, Kitteringham NR, McLaren AW, Miles JS, and Skett P, et al. (1992) Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J 281:359-368.
15. Gabrielsson J and Weiner D (2007) Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, Swedish Pharmaceutical Press, Stockholm, Sweden.
16. Gjerde J, Gandini S, Guerrieri-Gonzaga A, Haugan Moi LL, Aristarco V, Mellgren G, Decensi A, and Lien EA (2012) Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide. Breast Cancer Res Treat 134:693-700.
17. Gu J, Chen CS, Wei Y, Fang C, Xie F, Kannan K, Yang W, Waxman DJ, and Ding X (2007) A mouse model with liver-specific deletion and global suppression of the NADPH-cytochrome P450 reductase gene: characterization and utility for in vivo studies of cyclophosphamide disposition. J Pharmacol Exp Ther 321:9-17. (Pubitemid 46456993)
18. Hasegawa M, Kapelyukh Y, Tahara H, Seibler J, Rode A, Krueger S, Lee DN, Wolf CR, and Scheer N (2011) Quantitative prediction of human pregnane X receptor and cytochrome P450 3A4 mediated drug-drug interaction in a novel multiple humanized mouse line. Mol Pharmacol 80:518-528.
19. Henderson CJ, Otto DM, Carrie D, Magnuson MA, McLaren AW, Rosewell I, and Wolf CR (2003) Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J Biol Chem 278:13480-13486. (Pubitemid 36800122)
20. Hendrikx JJ, Lagas JS, Rosing H, Schellens JH, Beijnen JH, and Schinkel AH (2013) P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel. Int J Cancer 132:2439-2447.
21. Idkowiak J, Randell T, Dhir V, Patel P, Shackleton CH, Taylor NF, Krone N, and Arlt W (2012) A missense mutation in the human cytochrome b5 gene causes 46, XY disorder of sex development due to true isolated 17, 20 lyase deficiency. J Clin Endocrinol Metab 97:E465-475.
22. Jeffcoat R, Brawn PR, Safford R, and James AT (1977) Properties of rat liver microsomal stearoyl-coenzyme A desaturase. Biochem J 161:431-437. (Pubitemid 8025747)
23. Kariya K, Lee E, Yamaoka M, and Ishikawa H (1984) Selective induction of cytochrome b5 and NADH cytochrome b5 reductase by propylthiouracil. Life Sci 35:2327-2334. (Pubitemid 15217787)
24. Kaspera R, Naraharisetti SB, Evangelista EA, Marciante KD, Psaty BM, and Totah RA (2011) Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cyto-chrome P450 reductase and cytochrome b5. Biochem Pharmacol 82:681-691.
25. Kawata S, Sugiyama T, Seki K, Tarui S, Okamoto M, and Yamano T (1982) Stimulatory effect of cytochrome b5 induced by p-nitroanisole and diisopropyl 1, 3-dithiol-2-ylidenemalonate on rat liver microsomal drug hydroxylations. J Biochem 92:305-313. (Pubitemid 13067751)
26. Kominami S, Ogawa N, Morimune R, De-Ying H, and Takemori S (1992) The role of cyto-chrome b5 in adrenal microsomal steroidogenesis. J Steroid Biochem Mol Biol 42:57-64.
27. Kugler W, Pekrun A, Laspe P, Erdlenbruch B, and Lakomek M (2001) Molecular basis of recessive congenital methemoglobinemia, types I and II: Exon skipping and three novel missense mutations in the NADH-cytochrome b5 reductase (diaphorase 1) gene. Hum Mutat 17:348.
28. Kurian JR, Longlais BJ, and Trepanier LA (2007) Discovery and characterization of a cytochrome b5 variant in humans with impaired hydroxylamine reduction capacity. Pharmacogenet Genomics 17:597-603. (Pubitemid 47057709)
29. Lamb DC, Kaderbhai NN, Venkateswarlu K, Kelly DE, Kelly SL, and Kaderbhai MA (2001) Human sterol 14alpha-demethylase activity is enhanced by the membrane-bound state of cy-tochrome b(5). Arch Biochem Biophys 395:78-84. (Pubitemid 33030145)
30. Löfgren S, Hagbjörk AL, Ekman S, Fransson-Steen R, and Terelius Y (2004) Metabolism of human cytochrome P450 marker substrates in mouse: a strain and gender comparison. Xenobiotica 34:811-834. (Pubitemid 39546271)
31. Masubuchi Y, Iwasa T, Hosokawa S, Suzuki T, Horie T, Imaoka S, Funae Y, and Narimatsu S (1997) Selective deficiency of debrisoquine 4-hydroxylase activity in mouse liver microsomes. J Pharmacol Exp Ther 282:1435-1441. (Pubitemid 27408326)
32. McLaughlin LA, Ronseaux S, Finn RD, Henderson CJ, and Roland Wolf C (2010) Deletion of microsomal cytochrome b5 profoundly affects hepatic and extrahepatic drug metabolism. Mol Pharmacol 78:269-278.
33. Meehan RR, Forrester LM, Stevenson K, Hastie ND, Buchmann A, Kunz HW, and Wolf CR (1988) Regulation of phenobarbital-inducible cytochrome P-450s in rat and mouse liver following dexamethasone administration and hypophysectomy. Biochem J 254:789-797.
34. Pass GJ, Carrie D, Boylan M, Lorimore S, Wright E, Houston B, Henderson CJ, and Wolf CR (2005) Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse. Cancer Res 65: 4211-4217. (Pubitemid 40775659)
35. Perloff MD, von Moltke LL, Court MH, Kotegawa T, Shader RI, and Greenblatt DJ (2000) Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. J Pharmacol Exp Ther 292:618-628. (Pubitemid 30067425)
36. Porter TD (2002) The roles of cytochrome b5 in cytochrome P450 reactions. J Biochem Mol Toxicol 16:311-316.
37. Pritchard MP, Ossetian R, Li DN, Henderson CJ, Burchell B, Wolf CR, and Friedberg T (1997) A general strategy for the expression of recombinant human cytochrome P450s in Escherichia coli using bacterial signal peptides: expression of CYP3A4, CYP2A6, and CYP2E1. Arch Biochem Biophys 345:342-354. (Pubitemid 27400630)
38. Pritchard MP, Glancey MJ, Blake JA, Gilham DE, Burchell B, Wolf CR, and Friedberg T (1998) Functional co-expression of CYP2D6 and human NADPH-cytochrome P450 reductase in Escherichia coli. Pharmacogenetics 8:33-42. (Pubitemid 28097599)
39. Remacle J, Fowler S, Beaufay H, Amarcostesec A, and Berthet J (1976) Analytical study of microsomes and isolated subcellular membranes from rat liver. VI. Electron microscope examination of microsomes for cytochrome b5 by means of a ferritin-labeled antibody. J Cell Biol 71:551-564.
40. Sacco JC and Trepanier LA (2010) Cytochrome b5 and NADH cytochrome b5 reductase: genotype-phenotype correlations for hydroxylamine reduction. Pharmacogenet Genomics 20:26-37.
41. Scheer N, Ross J, Rode A, Zevnik B, Niehaves S, Faust N, and Wolf CR (2008) A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response. J Clin Invest 118:3228-3239.
42. Scheer N, Kapelyukh Y, Chatham L, Rode A, Buechel S, and Wolf CR (2012a) Generation and characterization of novel cytochrome P450 Cyp2c gene cluster knockout and CYP2C9 humanized mouse lines. Mol Pharmacol 82:1022-1029.
43. Scheer N, Kapelyukh Y, McEwan J, Beuger V, Stanley LA, Rode A, and Wolf CR (2012b) Modeling human cytochrome P450 2D6 metabolism and drug-drug interaction by a novel panel of knockout and humanized mouse lines. Mol Pharmacol 81:63-72.
44. Schenkman JB and Jansson I (2003) The many roles of cytochrome b5. Pharmacol Ther 97: 139-152.
45. Sonnichsen DS, Liu Q, Schuetz EG, Schuetz JD, Pappo A, and Relling MV (1995) Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 275:566-575. (Pubitemid 26025545)
46. Umbreit J (2007) Methemoglobin-it's not just blue: a concise review. Am J Hematol 82: 134-144. (Pubitemid 46155276)
47. Vieira LM, Kaplan JC, Kahn A, and Leroux A (1995) Four new mutations in the NADH-cytochrome b5 reductase gene from patients with recessive congenital methemoglobinemia type II. Blood 85:2254-2262.
48. Waskell L, Canova-Davis E, Philpot R, Parandoush Z, and Chiang JY (1986) Identification of the enzymes catalyzing metabolism of methoxyflurane. Drug Metab Dispos 14:643-648. (Pubitemid 17202400)
49. Wu C, Orozco C, Boyer J, Leglise M, Goodale J, Batalov S, Hodge CL, Haase J, Janes J, and Huss JW, 3rd, et al. (2009) BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol 10:R130.
50. Xu C, Ogburn ET, Guo Y, and Desta Z (2012) Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo. Drug Metab Dispos 40:717-725.
51. Yamaori S, Yamazaki H, Suzuki A, Yamada A, Tani H, Kamidate T, Fujita Ki, and Kamataki T (2003) Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7. Biochem Pharmacol 66: 2333-2340. (Pubitemid 37456741)
52. Yamazaki H, Johnson WW, Ueng YF, Shimada T, and Guengerich FP (1996) Lack of electron transfer from cytochrome b5 in stimulation of catalytic activities of cytochrome P450 3A4. Characterization of a reconstituted cytochrome P450 3A4/NADPH-cytochrome P450 reductase system and studies with apo-cytochrome b5. J Biol Chem 271:27438-27444. (Pubitemid 26367302)
53. Yamazaki H, Gillam EM, Dong MS, Johnson WW, Guengerich FP, and Shimada T (1997) Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450-b5 interactions. Arch Biochem Biophys 342:329-337. (Pubitemid 27251255)
54. Yamazaki H, Nakamura M, Komatsu T, Ohyama K, Hatanaka N, Asahi S, Shimada N, Guengerich FP, Shimada T, and Nakajima M, et al. (2002) Roles of NADPH-P450 reductase and apo-and holo-cytochrome b5 on xen obiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expr Purif 24:329-337. (Pubitemid 35420057)
55. Zhang H, Hamdane D, Im SC, and Waskell L (2008) Cytochrome b5 inhibits electron transfer from NADPH-cytochrome P450 reductase to ferric cytochrome P450 2B4. J Biol Chem 283: 5217-5225.
56. Zhang H, Myshkin E, and Waskell L (2005) Role of cytochrome b5 in catalysis by cytochrome P450 2B4. Biochem Biophys Res Commun 338:499-506. (Pubitemid 41540596)